Infectious Diseases
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Hantavirus Outbreak on Cruise Ship Raises Concerns Over Little-Known Infection
A hantavirus outbreak on the MV Hondius cruise ship has resulted in three fatalities, highlighting the need for awareness and diagnostic solutions for this rare but deadly virus.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Pipeline
NanoViricides has completed a $6 million capital raise to fund development of its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
Viral Infections Significantly Increase Heart Attack and Stroke Risk, Study Finds
New research reveals that both acute infections like influenza and COVID-19 and chronic viral infections including HIV and hepatitis C substantially elevate cardiovascular disease risks, highlighting the importance of preventive measures including vaccination.
New IDSA Guidelines Highlight Critical Need for Tailored COVID-19 Vaccines for Immunocompromised Population
GeoVax's GEO-CM04S1 vaccine addresses the significant protection gap for over 40 million immunocompromised Americans who experience limited effectiveness from current COVID-19 vaccines, as highlighted by new Infectious Diseases Society of America guidelines.
NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Nightmare Bacteria Infections Surge in U.S., Prompting Urgent Response from Biotech Sector
The rapid spread of antibiotic-resistant 'nightmare bacteria' in the United States is driving increased focus on biotech companies developing novel treatments to address this growing public health crisis.
NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025
NanoViricides will showcase its clinical-stage nanoviricide technology targeting multiple viral diseases at the LSX World Congress, highlighting its potential to address unmet medical needs through a novel antiviral approach.
Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
Erica Ollmann Saphire Honored with 2025 San Diego Genius Award for Pioneering Immunology Research
Dr. Erica Ollmann Saphire, a leading figure in immunology research, is set to receive the 2025 San Diego Genius Award for her groundbreaking work on viral infections and immune system responses, highlighting the intersection of science and community enrichment.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.
NanoViricides' NV-387 Shows Promise as Broad-Spectrum Antiviral with Strategic Pandemic Preparedness Value
NanoViricides, Inc. highlights NV-387's broad antiviral potential and its strategic importance for pandemic preparedness, with plans for a Phase II trial targeting MPox.
NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
NanoViricides, Inc. reports a significant breakthrough with its lead drug candidate, NV-387, showing increased survival rates in a lethal measles infection model, highlighting the potential for the first therapeutic option amid rising global measles cases.
NanoViricides Advances MPox Treatment Amid WHO's Extended Health Emergency
NanoViricides, Inc. progresses with NV-387, a broad-spectrum antiviral drug, as the WHO extends the MPox global health emergency, highlighting the drug's potential to fill gaps in current treatments.
GeoVax Advances Mpox Vaccine Development Amid Global Outbreak Concerns
GeoVax Labs accelerates its GEO-MVA vaccine candidate development following EMA's streamlined approval pathway, addressing the urgent need for diversified Mpox vaccine supply as global outbreaks expand.
NanoViricides Advances MPox Treatment with Adaptive Clinical Trial Design
NanoViricides, Inc. nears finalization of an adaptive clinical trial protocol for NV-387, a potential first-in-class treatment for MPox, highlighting its significance amid limited effective therapies.
Dutch Startup Innovates with Rapid Field Test for Infectious Diseases
Spotlight Diagnostics' new test kit offers a portable solution for detecting infectious diseases like malaria and Chlamydia, addressing the urgent need for accessible diagnostics amid rising disease prevalence due to climate change.
Study Reveals Critical Link Between WASH Access and Cholera in Low- and Middle-Income Countries
A recent study underscores the significant impact of water, sanitation, and hygiene (WASH) access on cholera prevalence in low- and middle-income countries, highlighting the need for targeted interventions to meet UN Sustainable Development Goals.
Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
Tonix Pharmaceuticals will present preclinical data on its TNX-801 mpox vaccine candidate at the Vaccine Congress 2025, highlighting its potential to address public health threats.
GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases
GeoVax Labs accelerates its GEO-MVA vaccine development for Mpox and smallpox, responding to global health threats and regulatory advancements.
GeoVax Secures Patent for Innovative Malaria Vaccine Design
GeoVax Labs, Inc. has been granted a U.S. patent for a novel vaccine construct aimed at preventing malaria, marking a significant step forward in the fight against the disease and other infectious threats.
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu
NanoViricides, Inc. highlights NV-387, its broad-spectrum antiviral candidate, as a potential game-changer in combating emerging COVID-19 variants and Bird Flu strains, showcasing its superior performance in animal models and readiness for cGMP manufacturing.
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
BiomX Inc. has reported successful Phase 2 clinical trial results for treating diabetic foot bone infections and cystic fibrosis with bacteriophage therapy, offering a potential solution to the growing antibiotic resistance crisis.